New data at CROI 2025 show zero cases of HIV acquisition reported with Apretude (cabotegravir long-acting (CAB LA) for PrEP) in varied clinical settings and populations in two implementation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback